Argent Biopharma (AU:RGT) has released an update.
Argent Biopharma Limited has announced a significant change in Director Roby Reuven Zomer’s interests, with the acquisition of 4,000,000 fully paid ordinary shares for a total consideration of A$1,640,000. This brings Zomer’s total holdings in the company to 5,292,321 shares through indirect interests. The change, referenced to a resolution in a recent notice of meeting, underscores a strengthening of the director’s stake in the firm.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
